Kazia Therapeutics
KZIA
9 hedge funds and large institutions have $262K invested in Kazia Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13% more funds holding
Funds holding: 8 → 9 (+1)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
50% less capital invested
Capital invested by funds: $527K → $262K (-$265K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$39.8K |
| 2 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$2.26K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.88K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$376 |
| 5 |
TSS
Two Sigma Securities
New York
|
+$376 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$47.6K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$28.7K |
| 3 |
VF
Virtu Financial
New York
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $158K | +$39.8K | +1,058 | +26% |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| $64K | -$47.6K | -1,265 | -38% |
|
|
OMC
3
Old Mission Capital
Chicago,
Illinois
| $26.3K | -$28.7K | -763 | -47% |
|
|
TSS
4
Two Sigma Securities
New York
| $7.52K | +$376 | +10 | +4% |
|
|
5
UBS Group
Zurich,
Switzerland
| $3.94K | +$1.88K | +50 | +65% |
|
|
BAM
6
Belpointe Asset Management
Reno,
Nevada
| $1.84K | +$2.26K | +60 | New |
|
7
Wells Fargo
San Francisco,
California
| $123 | – | – | – |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| $46 | – | – | – |
|
|
AF
9
Advisornet Financial
Minnetonka,
Minnesota
| $3 | – | – | – |
|
|
VF
10
Virtu Financial
New York
| – | -$14K | -246 | Closed |
|
|
NA
11
NewEdge Advisors
New Orleans,
Louisiana
| – | +$376 | +10 | New |
|
KZIA Hedge Fund Activity: Q4 2022 in Review
9 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q4 2022, worth a combined $262K — down 50% from $527K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KZIA positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $39.8K. The largest seller was Acadian Asset Management, cutting an estimated $47.6K.
- 9 institutional investors held Kazia Therapeutics (KZIA) as of Q4 2022, up from 8 in Q3 2022.
- Funds reported $262K of Kazia Therapeutics stock for Q4 2022, down 50% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q4 2022 and 1 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q4 2022 was Morgan Stanley, an estimated $39.8K added.
- The largest Kazia Therapeutics seller in Q4 2022 was Acadian Asset Management, an estimated $47.6K sold.
Based on aggregated 13F filings for Q4 2022.